• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Treanda (bendamustine hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Treanda (bendamustine hydrochloride)

  • Profile

Profile

Contact Information

Contact: Cephalon (Teva)
Website: https://www.treandahcp.com/

Currently Enrolling Trials

    Show More

    General Information

    Treanda is a rationally designed purine analog and alkylator hybrid. It damages the DNA in cancer cells, which leads to the normal path of cell death (apoptosis). It also stops cancer cells from dividing to create new cancer cells.

    Treanda is specifically indicated for: 1) the treatment of chronic lymphocytic leukemia where efficacy relative to first line therapies other than chlorambucil has not been established, and 2) indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

    Mechanism of Action

    Treanda contains bendamustine hydrochloride, an alkylating drug. Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. However, the exact mechanism of action of bendamustine remains unknown.

    Side Effects

    Adverse events associated with the use of Treanda for chronic lymphocytic leukemia may include, but are not limited to, the following:

    • Pyrexia
    • Nausea
    • Vomiting
    • Asthenia
    • Fatigue
    • Malaise
    • Weakness
    • Dry mouth
    • Somnolence
    • Cough
    • Constipation
    • Headache
    • Mucosal inflammation
    • Stomatitis

    Adverse events associated with the use of Treanda for the treatment of non-Hodgkin's lymphoma may include, but are not limited to, the following:

    • Nausea
    • Fatigue
    • Vomiting
    • Diarrhea
    • Pyrexia
    • Ratigue
    • Rebrile neutropenia
    • Pneumonia
    • Hypokalemia
    • Dehydration.

    Dosing/Administration

    Treanda is supplied as a powder in a 100 mg vial to be reconstituted with sterile water for intravenous administration. The recommended initial dose of the drug for the treatment of non-Hodgkin's lymphoma is 120 mg/m2 administered intravenously over 60 minutes on days one and two of a 21-day cycle, up to eight cycles. Treanda administration should be delayed in the event of a Grade 4 hematologic toxicity or clinically significant > Grade 2 non-hematologic toxicity.
    Dose modifications for hematologic toxicity: reduce the dose to 90 mg/m2 on days one1 and two of each cycle. If Grade 4 toxicity recurs, reduce the dose to 60 mg/m2 on days one and two of each cycle.
    Dose modifications for non-hematologic toxicity: reduce the dose to 90 mg/m2 on days one and two of each cycle. If Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m2 on days one and two of each cycle.

    The recommended initial dose of the drug for the treatment of chronic lymphocytic leukemia is 100 mg/m2 administered intravenously over 30 minutes on days one and two of a 28-day cycle, up to six cycles. Treanda administration should be delayed in the event of Grade 4 hematologic toxicity or clinically significant >Grade 2 non-hematologic toxicity.
    Dose modifications for hematologic toxicity: reduce the dose to 50 mg/m2 on days one and two of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m2 on days one and two of each cycle.
    Dose modifications for non-hematologic toxicity: reduce the dose to 50 mg/m2 on days one and two of each cycle.

    Clinical Trial Results

    FDA approval for Treanda for the treatment of chronic lymphocytic leukemia was based on the results of an open-label, randomized, controlled multicenter trial in 301 previously-untreated patients with Binet Stage B or C (Rai Stages I - IV) CLL requiring treatment. The subjects received either Treanda at 100 mg/m2, administered intravenously over a period of 30 minutes on days one and two or chlorambucil at 0.8 mg/kg administered orally on days one and 15 of each 28-day cycle. Efficacy endpoints were objective response rate and progression-free survival. The overall response rate was 59 percent in the Treanda arm compared to 26 percent in the chlorambucil arm (p).

    FDA approval for Treanda for the treatment of non-Hodgkin's lymphoma was based on the results of a single arm study of 100 subjects with indolent B-cell NHL that had progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. All subjects received Treanda intravenously at a dose of 120 mg/m2, on days one and two of a 21-day treatment cycle. They were treated for up to eight cycles. Overall response rate was seen in 74 of the subjects (64.3 percent). The median duration of response was 9.2 months.

    Additional Information

    For additional information regarding Treanda, chronic lymphocytic leukemia or non-Hodgkin's lymphoma, please visit the Treanda web page.

    Approval Date: 2008-10-01
    Company Name: Cephalon
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing